A phase II, randomized, open-label 3-arm clinical trial of fulvestrant (F) plus goserelin (G) versus anastrozole (A) plus goserelin (G) versus goserelin (G) alone for hormone receptor (HR) positive, tamoxifen (T) pretreated premenopausal women with recurrent or metastatic breast cance r(MBC) (KCSG BR10-04)

Category Primary study
ConferenceJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 207512bd14360f25524ff8961414cd24e81a67de
First added on: Feb 08, 2025